DDInter1702 DDInter1233
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Sorafenib {u} (Compound) upregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) is upregulated by {v} (Compound) Mitotane
Sorafenib {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is downregulated by {v} (Compound) Mitotane
Sorafenib {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Mitotane
Sorafenib {u} (Compound) upregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) is regulated by {v} (Gene) FAM69A
FAM69A {u} (Gene) is downregulated by {v} (Compound) Mitotane
Sorafenib {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is regulated by {v} (Gene) SERPINA6
SERPINA6 {u} (Gene) is bound by {v} (Compound) Mitotane
Sorafenib {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) regulates {v} (Gene) GJA1
GJA1 {u} (Gene) is downregulated by {v} (Compound) Mitotane
Sorafenib {u} (Compound) causes {v} (Side Effect) Dyspepsia
Dyspepsia {u} (Side Effect) is caused by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bisacodyl
Bisacodyl {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bisacodyl
Bisacodyl {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} (Compound) resembles {v} (Compound) Mitotane
Sorafenib (Compound) upregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is upregulated by Mitotane (Compound)
Sorafenib (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is downregulated by Mitotane (Compound)
Sorafenib (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Mitotane (Compound)
Sorafenib (Compound) upregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is regulated by FAM69A (Gene) and FAM69A (Gene) is downregulated by Mitotane (Compound)
Sorafenib (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is regulated by SERPINA6 (Gene) and SERPINA6 (Gene) is bound by Mitotane (Compound)
Sorafenib (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) regulates GJA1 (Gene) and GJA1 (Gene) is downregulated by Mitotane (Compound)
Sorafenib (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mitotane (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine (Compound) resembles Mitotane (Compound)